Trial · NCT07588438
Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.
NCT07588438, Phase 4, Recruiting, Las Rías Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. Trials, record NCT07588438. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07588438
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.
- NCT number
- NCT07588438
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 160 participants, estimated
- Lead sponsor
- Las Rías Medical Center
- Conditions
- Obesity, Diabetes Mellitus, Type 2
- Interventions
- Tirzepatide (LIPOLESS de Laboratorio de Productos Eticos C.E.I.S.A.)
- First posted
- 2026-05-14
- Last updated
- 2026-05-19
Source ClinicalTrials.gov
Registered outcomes32
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Percent Change From Baseline in Body Weight at 52 Weeks. | Baseline and 52 weeks. | Percentage change in total body weight from baseline to week 52 for participants in Cohort A (Adults with obesity without diabetes). |
| Primary | Mean Change From Baseline in Glycated Hemoglobin (HbA1c) at 52 Weeks. | Baseline and 52 weeks. | Absolute change in HbA1c levels from baseline to week 52 for participants in Cohort B (Adults with type 2 diabetes). |
| Primary | Number of Participants With Treatment-Emergent Adverse Events (TEAEs). | Through week 52. | Incidence, severity, and relationship of treatment-emergent adverse events (TEAEs), including gastrointestinal, pancreatic, cardiovascular, and other adverse events occurring during the 52-week treatment period. |
| Secondary | Mean Change From Baseline in Body Weight at 52 Weeks. | Baseline and 52 weeks. | Change in absolute body weight from baseline to week 52. |
| Secondary | Mean Change From Baseline in Body Mass Index (BMI) at 52 Weeks. | Baseline and 52 weeks. | Change in BMI calculated as weight in kilograms divided by height in meters squared (kg/m2). |
| Secondary | Percentage of Participants Achieving Body Weight Reduction Thresholds at 52 Weeks. | 52 weeks. | Percentage of participants achieving ≥5%, 10%, 15%, 20%, 25%, and 30% reduction from baseline body weight. |
| Secondary | Change From Baseline in Systolic Blood Pressure at 52 Weeks. | Baseline and 52 weeks. | Assessment of the absolute change in resting systolic blood pressure. |
| Secondary | Change From Baseline in Diastolic Blood Pressure at 52 Weeks. | Baseline and 52 weeks. | Assessment of the absolute change in resting diastolic blood pressure. |
| Secondary | Percentage Change From Baseline in Total Cholesterol at 52 Weeks. | Baseline and 52 weeks. | Assessment of percentage change in fasting total cholesterol concentrations from baseline to week 52. |
| Secondary | Percentage Change From Baseline in LDL Cholesterol (LDL-C) at 52 Weeks. | Baseline and 52 weeks. | Assessment of percentage change in fasting LDL cholesterol concentrations from baseline to week 52. |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07588438
GET https://conductscience.org/api/trials/v1/NCT07588438/registered?page=2